


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:37Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406195" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406195</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="d027071967" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Inorg Chem</journal-id><journal-id journal-id-type="iso-abbrev">Inorg Chem</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">ic</journal-id><journal-title-group><journal-title>Inorganic Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0020-1669</issn><issn pub-type="epub">1520-510X</issn><self-uri>pubs.acs.org/IC</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406195</article-id><article-id pub-id-type="pmcid-ver">PMC12406195.1</article-id><article-id pub-id-type="pmcaid">12406195</article-id><article-id pub-id-type="pmcaiid">12406195</article-id><article-id pub-id-type="pmid">40844241</article-id><article-id pub-id-type="doi">10.1021/acs.inorgchem.5c02026</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Understanding
the Modes of Action of &#946;&#8209;Ketoiminato
Iridium(III) Complexes in Cancer Cells</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e22-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7169577</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4439-131X</contrib-id><name name-style="western"><surname>Stringer</surname><given-names initials="T">Tameryn</given-names></name><xref rid="aff2" ref-type="aff"/><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7596754</contrib-id><name name-style="western"><surname>Yildirim</surname><given-names initials="B">B&#252;&#351;ra</given-names></name><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7596737</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6379-2362</contrib-id><name name-style="western"><surname>Sergi</surname><given-names initials="B">Baris</given-names></name><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6617472</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6408-3472</contrib-id><name name-style="western"><surname>Hofmann</surname><given-names initials="BJ">Benjamin J.</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7596758</contrib-id><name name-style="western"><surname>Lee</surname><given-names initials="YH">Yi-Hsuan</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">4148431</contrib-id><name name-style="western"><surname>Acilan</surname><given-names initials="C">Ceyda</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff5" ref-type="aff"/><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">2149892</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9981-129X</contrib-id><name name-style="western"><surname>Lord</surname><given-names initials="RM">Rianne M.</given-names></name><xref rid="cor2" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/><xref rid="aff2" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Department
of Chemistry</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">2707</institution-id><institution>University of Warwick</institution></institution-wrap>, <city>Coventry</city>
<postal-code>CV4 7AL</postal-code>, <country country="GB">United Kingdom</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution content-type="dept">School
of Chemistry, Pharmacy and Pharmacology</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">6106</institution-id><institution>University of East Anglia</institution></institution-wrap>, <city>Norwich</city>, <state>Norfolk</state>
<postal-code>NR4 7TJ</postal-code>, <country country="GB">United Kingdom</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution content-type="dept">School
of Science</institution>, <institution>The University of Waikato</institution>, <city>Hamilton</city>
<postal-code>3210</postal-code>, <country country="NZ">New Zealand</country>
</aff><aff id="aff4">
<label>&#8741;</label>
<institution content-type="dept">Graduate
School of Health Sciences</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">52979</institution-id><institution>Ko&#231; University</institution></institution-wrap>, <city>Istanbul</city>
<postal-code>34450</postal-code>, <country country="TR">Turkey</country>
</aff><aff id="aff5">
<label>&#8869;</label>
<institution>Ko&#231;
University Translational Research Center, KUTTAM</institution>, <city>Istanbul</city>
<postal-code>34450</postal-code>, <country country="TR">Turkey</country>
</aff><aff id="aff6">
<label>#</label>
<institution content-type="dept">School of
Medicine</institution>, <institution>Ko&#231; University</institution>, Sariyer, <city>Istanbul</city>
<postal-code>34450</postal-code>, <country country="TR">Turkey</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>cayhan@ku.edu.tr</email>.</corresp><corresp id="cor2"><label>*</label>Email: <email>Rianne.lord@warwick.ac.uk</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>01</day><month>9</month><year>2025</year></pub-date><volume>64</volume><issue>34</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>17189</fpage><lpage>17199</lpage><ext-link xlink:href="2392862" ext-link-type="ccdc">2392862</ext-link><ext-link xlink:href="2392863" ext-link-type="ccdc">2392863</ext-link><ext-link xlink:href="2392864" ext-link-type="ccdc">2392864</ext-link><ext-link xlink:href="2392865" ext-link-type="ccdc">2392865</ext-link><history><date date-type="received"><day>05</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>08</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>05</day><month>8</month><year>2025</year></date><date date-type="online"><day>22</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-22"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-22">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="ic5c02026.pdf"/><abstract><p>Four new charged iridium&#173;(III) 1,2,3,4,5-pentamethylcyclopentadienyl
(Cp*) complexes, <bold>1&#8211;4</bold>, of the type [Cp*Ir&#173;(<bold>L1&#8211;4</bold>)&#173;(PTA)]&#173;(PF<sub>6</sub>) (where <bold>L1&#8211;4</bold> = functionalized &#946;-ketoiminate ligands and PTA = 1,3,5-triaza-7-phosphaadamantane),
have been successfully synthesized and characterized. Single crystal
X-ray crystallographic data have been obtained for all compounds and
confirm a typical <italic toggle="yes">pseudo</italic>-octahedral half-sandwich
geometry. Cytotoxicity values have been determined against a range
of cancerous and noncancerous cell lines and highlight high cytotoxicity
and selectivity toward breast cancers. Among these compounds, the
unfunctionalized &#946;-ketoiminate Ir&#173;(III) complex (<bold>1</bold>) emerged as the most promising candidate, demonstrating activity
that was comparable to or exceeded that of cisplatin, especially after
24 h against the triple-negative MDA-MB-231 cell line. Morphological
and molecular analyses confirmed that <bold>1</bold> triggers apoptotic
cell death, involving caspase activation and PARP cleavage, which
is consistent with its DNA-damaging characteristics, highlighting
the future anticancer potential of compound <bold>1</bold>.</p></abstract><abstract abstract-type="graphical"><graphic position="float" orientation="portrait" xlink:href="ic5c02026_0014.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="ic5c02026_0012.jpg"/></abstract><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>Medical Research Council</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100000265</institution-id></institution-wrap></funding-source><award-id>MR/T041315/1</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ic5c02026</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ic5c02026</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>a5d885618b9858f2c143754eeb583142ab50b0e35e0d4f083b2a39b835aabe44</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Platinum-based anticancer drugs such as
cisplatin have a range
of complications associated with their administration, including negative
and toxic side effects and intrinsic/acquired resistance.<xref rid="ref1" ref-type="bibr"/> These drugs are also limited to treating specific
types of cancers.<xref rid="ref2" ref-type="bibr"/> Medicinal inorganic
chemists have since focused on developing molecules which can overcome
these constraints, creating new drugs with high but targeting cytotoxicity,
different intracellular modes of action and the ability to treat platinum-resistant
tumors; all in the hope to reduce the devastating patient side-effects
associated with current clinical metallodrugs.<xref rid="ref3" ref-type="bibr"/>
</p><p>Metallodrugs containing platinum-group metals (PGMs), e.g.,
ruthenium,
osmium, rhodium, and iridium, have shown promising biological properties
in recent years.<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>&#8722;<xref rid="ref5" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref6" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref7" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref8" ref-type="bibr"/>
</named-content> Organometallic half-sandwich compounds, specifically those based
on Ru&#173;(II), have generated significant interest for their bioapplications,<xref rid="ref9" ref-type="bibr"/> including RM175 (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>A) a ethylenediamine compound by Sadler and
co-workers,<xref rid="ref10" ref-type="bibr"/> and both RAPTA-T and RAPTA-C
1,3,5-triaza-7-phosphoadamantane (PTA) compounds (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>B,C) by Dyson and co-workers,<xref rid="ref11" ref-type="bibr"/> which all show impressive activity.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>A range of
bioactive half-sandwich PGM compounds.</p></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="ic5c02026_0001.jpg"/></fig><p>Other PGM compounds, for example, those based on
un/functionalized
pentamethylcyclopentadienyl (Cp*)-Ir&#173;(III) and Rh&#173;(III) motifs, have
been readily modified to improve lipophilicity and subsequently improve
activity.<named-content content-type="bibref-group">
<xref rid="ref8" ref-type="bibr"/>,<xref rid="ref12" ref-type="bibr"/>,<xref rid="ref13" ref-type="bibr"/>
</named-content> Both neutral
and cationic Cp*-Ir&#173;(III) compounds containing a variety of bidentate
ligands, for example, coordination through <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic> and <italic toggle="yes">N</italic>,<italic toggle="yes">C</italic> ligands (e.g., <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>D,E), are reported
to induce apoptosis,<xref rid="ref14" ref-type="bibr"/> and changing the
chelating <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-ligand for a <italic toggle="yes">N</italic>,<italic toggle="yes">C</italic>-ligand led to a significant improvement
in bioactivity.<xref rid="ref15" ref-type="bibr"/> PGM compounds with &#946;-diketone
(<italic toggle="yes">O</italic>,<italic toggle="yes">O</italic>) ligands have been reported
by us and others (e.g., <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>F); however, the <italic toggle="yes">O</italic>,<italic toggle="yes">O</italic>-ligands
yielded poorly cytotoxic compounds when compared to previously reported <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic> and <italic toggle="yes">N</italic>,<italic toggle="yes">C</italic> compounds.<named-content content-type="bibref-group">
<xref rid="ref16" ref-type="bibr"/>,<xref rid="ref17" ref-type="bibr"/>
</named-content>
</p><p>To allow comparisons of
ligand effects, we also reported both arene-Ru&#173;(II)
and Cp*-Ir&#173;(III) compounds containing <italic toggle="yes">N</italic>,<italic toggle="yes">O</italic> &#946;-ketoiminate ligands,<named-content content-type="bibref-group">
<xref rid="ref17" ref-type="bibr"/>,<xref rid="ref18" ref-type="bibr"/>
</named-content> and showed their cytotoxicity
was significantly higher than the corresponding <italic toggle="yes">O</italic>,<italic toggle="yes">O</italic> &#946;-diketonato compounds. Notably, compounds
of the type [Cp*Ir&#173;(<italic toggle="yes">N</italic>,<italic toggle="yes">O</italic>)&#173;Cl] (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>G) were shown to
have moderate to high cytotoxicity against various cancer cell lines,
with increased activity against colorectal cancer, and higher cancer
cell line selectivity than cisplatin.<xref rid="ref19" ref-type="bibr"/>
</p><p>PGM compounds, which are modified with PTA ligands, have consistently
shown improvements in solubility while either maintaining or improving
activity.<xref rid="ref20" ref-type="bibr"/> This study focuses on understanding
the biological effects of incorporating PTA ligands into our previously
reported &#946;-ketoiminato Cp*-Ir&#173;(III) chlorido compounds. Comparisons
have been made with a small range of compounds that exhibited low-moderate
(R = H, 2&#8242;,4&#8242;-diCl) or moderate-high (R = 4&#8242;-Br,
4&#8242;-OEt) cytotoxicity.<xref rid="ref19" ref-type="bibr"/> Herein,
we report their preparation, structural characterization and evaluation
of their biological <italic toggle="yes">in vitro</italic> modes of action using
DNA, apoptosis, caspase, and microscopy assays.</p></sec><sec id="sec2"><title>Results and Discussion</title><sec id="sec2.1"><title>Synthesis and Characterization</title><p>The &#946;-ketoiminate
ligands <bold>L1&#8211;4</bold> were synthesized and isolated according
to our previously reported methods,<named-content content-type="bibref-group">
<xref rid="ref17" ref-type="bibr"/>&#8722;<xref rid="ref18" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref19" ref-type="bibr"/>
</named-content> and used in the preparation
of four new charged Cp*-Ir&#173;(III) PTA compounds <bold>1&#8211;4</bold> (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>). All new
compounds were isolated in moderate yields (46&#8211;69%) and characterized
by <sup>1</sup>H, <sup>13</sup>C&#173;{<sup>1</sup>H} and <sup>31</sup>P&#173;{<sup>1</sup>H} NMR spectroscopy (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Figures S1&#8211;S12</ext-link>), elemental analysis, high-resolution mass spectrometry (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Figures S33&#8211;S36</ext-link>), and single-crystal X-ray
diffraction (scXRD). <sup>1</sup>H NMR spectra show the characteristic
resonances for the methine singlet between 6.0&#8211;5.4 ppm, the
disappearance of the free ligand NH at <italic toggle="yes">ca</italic>. 13 ppm
and new PTA resonances between 4.4&#8211;4.7 ppm. <sup>13</sup>C&#173;{<sup>1</sup>H} NMR spectra show successful formation with the PTA ligand
appearing as doublets at <italic toggle="yes">ca</italic>. 73 and 50 ppm due to
the <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) and <sup>1</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) coupling, respectively. While the <sup>31</sup>P&#173;{<sup>1</sup>H} NMR spectra show the two phosphorus environments for the
PTA ligand, a singlet at <italic toggle="yes">ca</italic>. &#8722;61 ppm, and
the PF<sub>6</sub> anion, a septet at <italic toggle="yes">ca</italic>. &#8722;144
ppm.</p><fig position="float" id="sch1" fig-type="scheme" orientation="portrait"><label>1</label><caption><title>Synthetic Procedures for Compounds <bold>1-4</bold> from Ligands <bold>L1-4</bold>
</title></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="ic5c02026_0011.jpg"/></fig></sec><sec id="sec2.2"><title>Stability Studies</title><p>
<sup>1</sup>H and <sup>31</sup>P
NMR spectra were used to support the stability studies, and compounds <bold>1&#8211;4</bold> were dissolved in a mixture of 90% DMSO-<italic toggle="yes">d</italic>
<sub>6</sub> and 10% D<sub>2</sub>O and NMR spectra collected
over 96 h. Representative NMR spectra at the start, and then after
12, 24, and 96 h are presented in the Supporting Information (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Figures S13&#8211;S20</ext-link>), and show no hydrolysis
or decomposition of the compounds over this period, which is in line
with previously reported &#946;-diketonato Cp*-Ir&#173;(III) PTA complexes
by Pettinari et al.<xref rid="ref21" ref-type="bibr"/>
</p><p>Pettinari et
al. showed that in the presence of elevated chloride concentrations,
similar to those found in blood serum or cell culture media (DMEM,
RPMI), the ligands dissociate, and the respective Cp*-Ir&#173;(III) chlorido
complexes are formed. To test whether this is the case for complexes <bold>1&#8211;4</bold>, stabilities were assessed over 96 h in 70% DMSO-<italic toggle="yes">d</italic>
<sub>6</sub> and 30% D<sub>2</sub>O mixtures spiked with
0.1 M NaCl (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Figures S21&#8211;S28</ext-link>). In
contrast to the discussed &#946;-diketonato complexes, no decomposition
was observed with complexes <bold>1&#8211;4</bold>, demonstrating
the stronger donor properties of the &#946;-ketoiminate ligands and
higher stability of the complexes. This was also confirmed by analyzing
the HR-MS spectra after the compounds (in the same conditions) were
incubated for 96 h. The spectra show no DMSO adducts and only <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> values for [M-PF<sub>6</sub>] and [M-PF<sub>6</sub>&#8211;PTA] (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Figures S37&#8211;S40</ext-link>) were observed.</p><p>Due to low solubility, the percentage of water
could not be increased
further in the NMR studies; therefore, ultraviolet/visible (UV/vis)
stability studies were conducted using compounds <bold>1&#8211;4</bold> in fully supplemented phenol-red free media over 96 h at 37 &#176;C.
Unlike the NMR experiments, the UV/vis spectra (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Figures S29&#8211;S32</ext-link>) show that all compounds hydrolyze
in high concentrations of water and the complex environment of the
media. The rate of decomposition is dependent on the substitution
pattern where compound <bold>1</bold> fully decomposes after <italic toggle="yes">ca.</italic> 90 h, the compounds (<bold>2</bold> and <bold>4</bold>) are significantly less stable and no changes in the spectra are
observed after 64 and 72 h, respectively, and the highest stability
is observed for compound <bold>3</bold> (&gt;96 h).</p></sec><sec id="sec2.3"><title>Single Crystal X-ray Diffraction (scXRD)</title><p>Yellow-orange
single crystals of complexes <bold>1&#8211;4</bold> suitable for
scXRD analysis were grown by slow evaporation of a concentrated solution
of acetone at room temperature (CSD: 239282&#8211;<ext-link xlink:href="2392865" ext-link-type="ccdc">2392865</ext-link>). The structural solutions were performed in monoclinic
(<bold>1&#8211;3</bold>; <italic toggle="yes">P</italic>2<sub>1</sub>/<italic toggle="yes">c</italic> and <italic toggle="yes">P</italic>2<sub>1</sub>/<italic toggle="yes">n</italic>) or triclinic (<bold>4</bold>; <italic toggle="yes">P</italic>1&#773;) space
groups, with either one or three molecules in the unit cell. The molecular
structures are shown in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>, and all bond lengths (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>) and bond angles (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Table S2</ext-link>) are in the range of the previously reported Cp*-Ir&#173;(III) complexes.<xref rid="ref19" ref-type="bibr"/> Other crystallographic data are presented in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Table S1</ext-link> of the Supporting Information.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>Molecular structures
of complexes <bold>1&#8211;4</bold>. Hydrogen
atoms and hexafluorophosphate anions are omitted for clarity, and
displacement ellipsoids are placed at the 50% probability level.</p></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="ic5c02026_0002.jpg"/></fig><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>Bond Lengths (&#197;) of Complexes <bold>1-4</bold> with s.u.s in Parentheses</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">bond lengths (&#197;)</th><th align="center" colspan="1" rowspan="1">
<bold>1</bold>
</th><th align="center" colspan="1" rowspan="1">
<bold>2</bold>
</th><th align="center" colspan="1" rowspan="1">
<bold>3</bold>
</th><th align="center" colspan="1" rowspan="1">
<bold>4</bold>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>Ir1&#8211;P1</bold>
</td><td align="left" colspan="1" rowspan="1">2.3164(12)</td><td align="left" colspan="1" rowspan="1">2.2964(7)</td><td align="left" colspan="1" rowspan="1">2.3190(9)</td><td align="left" colspan="1" rowspan="1">2.3022(16)/2.3049(17)/2.3212(19)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Ir1&#8211;O1</bold>
</td><td align="left" colspan="1" rowspan="1">2.115(4)</td><td align="left" colspan="1" rowspan="1">2.1014(18)</td><td align="left" colspan="1" rowspan="1">2.088(2)</td><td align="left" colspan="1" rowspan="1">2.093(5)/2.097(4)/2.080(5)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Ir1&#8211;N1</bold>
</td><td align="left" colspan="1" rowspan="1">2.108(4)</td><td align="left" colspan="1" rowspan="1">2.122(2)</td><td align="left" colspan="1" rowspan="1">2.101(3)</td><td align="left" colspan="1" rowspan="1">2.108(5)/2.112(6)/2.106(5)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>C1&#8211;O1</bold>
</td><td align="left" colspan="1" rowspan="1">1.294(6)</td><td align="left" colspan="1" rowspan="1">1.296(3)</td><td align="left" colspan="1" rowspan="1">1.292(4)</td><td align="left" colspan="1" rowspan="1">1.313(7)/1.300(8)/1.290(8)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>C3&#8211;N1</bold>
</td><td align="left" colspan="1" rowspan="1">1.324(7)</td><td align="left" colspan="1" rowspan="1">1.317(3)</td><td align="left" colspan="1" rowspan="1">1.326(4)</td><td align="left" colspan="1" rowspan="1">1.322(9)/1.300(9)/1.339(9)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Ir-Cp*&#160;centroid</bold>
</td><td align="left" colspan="1" rowspan="1">1.832</td><td align="left" colspan="1" rowspan="1">1.843</td><td align="left" colspan="1" rowspan="1">1.842</td><td align="left" colspan="1" rowspan="1">1.832/1.834/1.844</td></tr></tbody></table></table-wrap></sec><sec id="sec2.4"><title>Chemosensitivity Studies</title><p>Chemosensitivity studies were
conducted using human cell lines: breast adenocarcinomas MDA-MB-231
and MCF-7, pancreatic carcinoma MIA PaCa-2 and a noncancerous retinal
epithelial cell line ARPE-19, after being incubated for 96 h with
compounds <bold>1&#8211;4</bold>, cisplatin (CDDP) or carboplatin
(CARB) (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref> and <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>). The ligands and
the Cp*-Ir&#173;(III) dimer precursor have already been screened and show
no or low cytotoxicity.<named-content content-type="bibref-group">
<xref rid="ref17" ref-type="bibr"/>,<xref rid="ref19" ref-type="bibr"/>,<xref rid="ref22" ref-type="bibr"/>
</named-content> Generally, <bold>1&#8211;4</bold> exhibit moderate to high cytotoxicity
against MDA-MB-231 and MIA PaCa-2, with IC<sub>50</sub> values ranging
from 4.1 &#177; 0.5 &#956;M (MDA-MB-231, <bold>4</bold>) to 14.9
&#177; 0.7 &#956;M (MIA PaCa-2, <bold>2</bold>). However, the cytotoxicity
is significantly reduced against MCF-7, with IC<sub>50</sub> values
ranging from 32.4 &#177; 0.3 &#956;M (<bold>3</bold>) to 48 &#177;
3 &#956;M (<bold>1</bold>). Compounds <bold>1&#8211;4</bold> are
less active than CDDP against all cell lines tested (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Figure S41</ext-link>); however, they have increased selectivity when
compared to CARB, with IC<sub>50</sub> values between 2.7&#8211;4.4x
higher against MIA PaCa-2 and 2.5&#8211;3.9x higher against MDA-MB-231
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Figure S42</ext-link>).</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>IC<sub>50</sub> values
(&#956;M) &#177; SD for compounds <bold>1&#8211;4</bold>, cisplatin
(CDDP) and carboplatin (CARB): Cancer
cell lines MDA-MB-231, MCF-7, MIA PaCa-2, and noncancerous cell line
ARPE-19 were exposed to the compounds for 96 h (<italic toggle="yes">n</italic> = 9).</p></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="ic5c02026_0003.jpg"/></fig><table-wrap position="float" id="tbl2" orientation="portrait"><label>2</label><caption><title>IC<sub>50</sub> Values (&#956;M)
&#177; SD for Compounds <bold>1-4</bold>, Cisplatin (CDDP) and Carboplatin
(CARB) When Tested against MDA-MB-231, MCF-7, MIA PaCa-2 and ARPE-19
Cells for 96 h (or 24 h) (<italic toggle="yes">n</italic> = 9)<xref rid="t2fn1" ref-type="table-fn"/>
</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="4" align="center" rowspan="1">96&#160;h<hr/></th><th align="center" colspan="1" rowspan="1">24&#160;h<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">complex</th><th align="center" colspan="1" rowspan="1">MDA-MB-231</th><th align="center" colspan="1" rowspan="1">MCF-7</th><th align="center" colspan="1" rowspan="1">MIA&#160;PaCa-2</th><th align="center" colspan="1" rowspan="1">ARPE-19</th><th align="center" colspan="1" rowspan="1">MDA-MB-231</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>1</bold>
</td><td align="left" colspan="1" rowspan="1">6.3&#160;&#177;&#160;0.7 (1.7)</td><td align="left" colspan="1" rowspan="1">48&#160;&#177;&#160;3 (0.2)</td><td align="left" colspan="1" rowspan="1">9&#160;&#177;&#160;1 (1.2)</td><td align="left" colspan="1" rowspan="1">10.4&#160;&#177;&#160;0.7</td><td align="left" colspan="1" rowspan="1">18&#160;&#177;&#160;1</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>2</bold>
</td><td align="left" colspan="1" rowspan="1">5.4&#160;&#177;&#160;0.3 (3.0)</td><td align="left" colspan="1" rowspan="1">45.1&#160;&#177;&#160;0.8 (0.4)</td><td align="left" colspan="1" rowspan="1">14.9&#160;&#177;&#160;0.7 (1.1)</td><td align="left" colspan="1" rowspan="1">16&#160;&#177;&#160;1</td><td align="left" colspan="1" rowspan="1">21&#160;&#177;&#160;1</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>3</bold>
</td><td align="left" colspan="1" rowspan="1">4.8&#160;&#177;&#160;0.5 (3.0)</td><td align="left" colspan="1" rowspan="1">32.4&#160;&#177;&#160;0.3 (0.5)</td><td align="left" colspan="1" rowspan="1">11.2&#160;&#177;&#160;0.1 (1.3)</td><td align="left" colspan="1" rowspan="1">14.6&#160;&#177;&#160;0.8</td><td align="left" colspan="1" rowspan="1">22&#160;&#177;&#160;1</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>4</bold>
</td><td align="left" colspan="1" rowspan="1">4.1&#160;&#177;&#160;0.5 (2.6)</td><td align="left" colspan="1" rowspan="1">34.3&#160;&#177;&#160;0.6 (0.3)</td><td align="left" colspan="1" rowspan="1">10&#160;&#177;&#160;1 (1.1)</td><td align="left" colspan="1" rowspan="1">10.7&#160;&#177;&#160;0.4</td><td align="left" colspan="1" rowspan="1">36&#160;&#177;&#160;1</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>CDDP</bold>
</td><td align="left" colspan="1" rowspan="1">2.2&#160;&#177;&#160;0.3 (2.7)</td><td align="left" colspan="1" rowspan="1">6.1&#160;&#177;&#160;0.9 (1.0)</td><td align="left" colspan="1" rowspan="1">3.9&#160;&#177;&#160;0.6 (1.5)</td><td align="left" colspan="1" rowspan="1">6.0&#160;&#177;&#160;0.2</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>CARB</bold>
</td><td align="left" colspan="1" rowspan="1">16&#160;&#177;&#160;1 (&gt;6.3)</td><td align="left" colspan="1" rowspan="1">40&#160;&#177;&#160;1 (&gt;2.5)</td><td align="left" colspan="1" rowspan="1">40&#160;&#177;&#160;4 (&gt;2.5)</td><td align="left" colspan="1" rowspan="1">&gt;100</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Selectivity index (SI) values are
shown in parentheses.</p></fn></table-wrap-foot></table-wrap><p>The cytotoxicity of the compounds against the cancer
cell lines
was also compared to the noncancerous retinal epithelial cell line,
ARPE-19, to determine the possibility of cancer cell selectivity.
The cytotoxic values are generally high for all compounds, meaning
low selectivity is observed, e.g., SI = 0.2&#8211;0.5 or 1.1&#8211;1.3
against MCF-7 and MIA PaCa-2, respectively (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref> parentheses). Slight improvements in selectivity
were observed against MDA-MB-231, with SI = 1.7&#8211;3.3.</p><p>The compounds generally performed consistently better against the
triple-negative breast cell line, MDA-MB-231; therefore, the activity
was also investigated after 24 h against this cell line (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>). Compound <bold>1</bold> exhibits slightly higher activity when compared to <bold>2</bold>-<bold>3</bold> and significantly higher activity when compared
to compound <bold>4</bold>, CDDP and CARB. Therefore, in the following
sections, an in-depth analysis of the modes of action was performed
using compound <bold>1</bold> against MDA-MB-231, and in several cases,
the activity is compared to the hormone-dependent breast cancer cell
line, MCF-7 (results are shown in the <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link>).</p></sec><sec id="sec2.5"><title>Generation of Reactive Oxygen Species (ROS)</title><p>ROS production
in cells has been reported after treatment with Cp*-Ir&#173;(III) complexes,
by a range of pathways including NADH oxidation and induction of oxidative
stress,<named-content content-type="bibref-group">
<xref rid="ref23" ref-type="bibr"/>&#8722;<xref rid="ref24" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref25" ref-type="bibr"/>
</named-content> indirectly due to the expression of specific proteins,
whose levels are regulated by oxidative stress defense pathways,<named-content content-type="bibref-group">
<xref rid="ref26" ref-type="bibr"/>,<xref rid="ref27" ref-type="bibr"/>
</named-content> or via interaction with biomolecules such as glutathione (GSH),
which is a crucial antioxidant in cells.<xref rid="ref28" ref-type="bibr"/>
</p><p>To measure the degree of ROS produced in MDA-MB-231 cells,
2&#8242;,7&#8242;-dichlorodihydrofluorescein diacetate (H<sub>2</sub>DCFDA), a cell-permeable fluorescent dye, was used. H<sub>2</sub>DCFDA is deacetylated by esterases and consecutively oxidized by
intracellular ROS into a fluorescent molecule, dichlorofluorescein
(DCF).<xref rid="ref29" ref-type="bibr"/> Due to its slightly enhanced activity
in the MDA-MB-231 cell line after 24 h, the cell line was treated
for 4 h with 100 &#956;M of compound <bold>1</bold> (IC<sub>50</sub> = 18 &#177; 1 &#956;M after 24 h), and compared to a nontreated
control. As shown in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>, treatment with <bold>1</bold> leads to an increase in fluorescence,
which suggests that ROS generation could be a plausible mode of action;
however, further studies would be required to determine the pathways
by which this ROS is generated.</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Reactive oxygen species (ROS) after MDA-MB-231
cells were treated
with 100 &#956;M of compound <bold>1</bold> for 4 h at 37 &#176;C
and compared to an untreated control. Scale bar = 50 &#956;m.</p></caption><graphic id="gr5" position="float" orientation="portrait" xlink:href="ic5c02026_0004.jpg"/></fig></sec><sec id="sec2.6"><title>DNA Studies</title><p>The ability of compounds to intercalate,
nick, or cleave DNA can be evaluated using gel electrophoresis with
plasmid DNA. In this study, <italic toggle="yes">in vitro</italic> plasmid DNA
assays were performed by incubating 200 ng of plasmid DNA with different
concentrations (100&#8211;400 &#956;M) of <bold>1</bold> or CDDP,
which served as a positive control. The DNA fragments were then separated
via agarose gel electrophoresis, and potential changes in DNA migration
patterns were analyzed.</p><p>Treatment with <bold>1</bold> did not
induce any apparent shift in plasmid DNA migration. While a slight
reduction in the nicked circular form was observed, this difference
was not statistically significant (<italic toggle="yes">p</italic> = 0.73), and
the distribution of both supercoiled and nicked forms remained largely
unchanged across concentrations. In contrast, CDDP treatment resulted
in faster DNA migration, consistent with its well-known DNA coordination
and our previously reported findings.<xref rid="ref30" ref-type="bibr"/> These results suggest that <bold>1</bold> does not significantly
interact with or damage DNA under cell-free conditions (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>). These results are in line
with other reported Ir&#173;(III) complexes, where no DNA cleavage was observed
even at very high concentrations of the complexes. DNA was found not
to be the target for the complexes, but potentially targeted lysosomes
instead.<named-content content-type="bibref-group">
<xref rid="ref24" ref-type="bibr"/>,<xref rid="ref25" ref-type="bibr"/>
</named-content> This experiment does not rule out DNA as
a target of these complexes but does suggest that the complexes could
act by more than one mechanism or have more than one biomolecular
target.</p><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>Plasmid DNA (200 ng) was incubated with varying concentrations
(100, 200, and 400 &#956;M) of compound <bold>1</bold> or CDDP for
24 h at room temperature. The DNA was then separated via agarose gel
electrophoresis, and the intensity of supercoiled and nicked circular
DNA bands was quantified and expressed as mean &#177; SEM (<italic toggle="yes">n</italic> = 4).</p></caption><graphic id="gr6" position="float" orientation="portrait" xlink:href="ic5c02026_0005.jpg"/></fig><sec id="sec2.6.1"><title>Evaluation of Cell Death through Morphological Analysis</title><p>To investigate how the drugs impacted cell viability, acridine orange
(AO)/ethidium bromide (EtBr) staining was employed to identify the
MDA-MB-231 cells' mode of death in response to compound <bold>1</bold> or CDDP, with AO marking early apoptotic cells in green
and EtBr
marking late apoptotic or necrotic cells in red. As shown in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>, untreated controls
displayed a faint AO signal and no EtBr staining, as expected. In
contrast, treatment with <bold>1</bold> resulted in increased staining
for both dyes, suggesting a predominant increase in apoptotic cell
death. This effect was more pronounced than with CDDP, indicating
its higher efficacy.</p><fig position="float" id="fig6" fig-type="figure" orientation="portrait"><label>6</label><caption><p>MDA-MB-231 cells after treatment with compound <bold>1</bold> or
CDDP and evaluation of apoptosis using acridine orange/ethidium bromide
(AO/EB) staining. The stained cells were observed under an Eclipse
TS100 Nikon fluorescence microscope. Scale = 100 &#956;m.</p></caption><graphic id="gr7" position="float" orientation="portrait" xlink:href="ic5c02026_0006.jpg"/></fig><p>The potential of compound <bold>1</bold> to trigger
apoptosis in
breast cancer cells was then studied. Morphological analysis of cellular
nuclei revealed typical apoptotic features like DNA fragmentation
and condensation, confirming apoptosis as the primary form of cell
death in MDA-MB-231 cells (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>). High-magnification insets (1&#8211;6) illustrate
representative nuclear morphologies captured in the assay. Condensed,
hyperintense nuclei with reduced area (e.g., images 1, 2 and 3), irregular
nuclear blebs with discontinuous chromatin (e.g., images 3 and 4),
and fragmented chromatin consistent with apoptotic bodies (e.g., images
5 and 6). These results were consistent with the findings in MCF-7
cells (see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Figure S43</ext-link>), suggesting that
the results are not specific to a single cell line.</p><fig position="float" id="fig7" fig-type="figure" orientation="portrait"><label>7</label><caption><p>Microscopic visualization
of nuclear morphology changes in MDA-MB-231
breast cancer cells after 48 h exposure to compound <bold>1</bold> or CDDP. Nuclear DNA was stained with DAPI, which intercalates into
double-stranded DNA and fluoresces blue, allowing visualization of
chromatin organization. Apoptotic alterations were observed, including
nuclear shrinkage (arrowheads), chromatin condensation (appearing
as smaller, hyperintense nuclei due to higher DNA packing), and DNA
fragmentation forming apoptotic bodies (arrows). High-magnification
insets (1&#8211;6) illustrate representative nuclear morphologies:
condensed, intensely stained nuclei with reduced area (1&#8211;3),
irregular nuclear blebs with discontinuous chromatin (3&#8211;4),
and fragmented chromatin forming discrete apoptotic bodies (5&#8211;6).
These morphological features confirm apoptosis as the predominant
form of cell death. Images were acquired using a Leica DMI8 fluorescence
microscope at 40&#215; magnification. Scale bar = 50 &#956;m.</p></caption><graphic id="gr8" position="float" orientation="portrait" xlink:href="ic5c02026_0007.jpg"/></fig></sec><sec id="sec2.6.2"><title>Molecular Assessment of Cell Death</title><p>To assess whether
apoptotic markers responded as anticipated, changes in Annexin V staining
(<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>, top) and
caspase activity in MDA-MB-231 cells (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>, bottom) with compound <bold>1</bold> and
CDDP were measured. Annexin V detects changes in membrane integrity,
while caspases function as executioner enzymes, cleaving specific
cellular proteins during apoptosis. Both assays showed a significant
increase in apoptotic cells following treatment with <bold>1</bold>. Interestingly, while morphological assays revealed a higher proportion
of apoptotic cells compared to CDDP, Annexin V staining and caspase
activity were less pronounced, likely due to differences in the timing
of the experiment&#8217;s end point (which was 48 h for morphological
assays and 72 h for flow cytometric assays). This suggests distinct
cellular response kinetics between <bold>1</bold> and CDDP, despite
both treatments ultimately leading to apoptosis. Similar trends were
observed in MCF-7 cells across both assays (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Figure S44</ext-link>).</p><fig position="float" id="fig8" fig-type="figure" orientation="portrait"><label>8</label><caption><p>Flow cytometric analysis to assess induction of apoptosis
by Annexin
V/7-AAD positivity (top) and Caspase 3/7 activity (bottom). MDA-MB-231
cells were treated with compound <bold>1</bold> or CDDP at half inhibitory
concentrations for 72 h and analyzed using the Muse Cell Analyzer.</p></caption><graphic id="gr9" position="float" orientation="portrait" xlink:href="ic5c02026_0008.jpg"/></fig><p>Lastly, PARP cleavage was used to assess apoptosis,
as it serves
as a hallmark of caspase activation and confirms the apoptotic process
by indicating DNA damage response inactivation (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>). The results once again supported apoptosis
as the primary form of cell death, with a clear increase in cleaved
PARP observed at levels comparable to those seen with cisplatin. Consistent
findings were again observed in MCF-7 cells (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Figure S45</ext-link>).</p><fig position="float" id="fig9" fig-type="figure" orientation="portrait"><label>9</label><caption><p>Quantification of PARP cleavage activation as an apoptosis
marker
after MDA-MB-231 cells were treated for 48 h with IC<sub>50</sub> and
IC<sub>75</sub> doses of compound <bold>1</bold> and CDDP as a positive
control. Left panel shows the Western blot images of cleaved and full-length
PARP while the graph displays the quantification of band intensities.</p></caption><graphic id="gr10" position="float" orientation="portrait" xlink:href="ic5c02026_0009.jpg"/></fig></sec></sec><sec id="sec2.7"><title>Three-Dimensional (3D) Cell Culture</title><p>3D cell cultures
of cancer are good models for preclinical cancer research, as they
are more representative of tumor microenvironments.<xref rid="ref31" ref-type="bibr"/> MDA-MB-231 cells were maintained using the standard cell
culture methods before seeding into round-bottom ultralow-attachment
plates for 3D culture. Once the cells were seeded, the plate was centrifuged
to assist with cell clumping at the bottom of the well and facilitate
uniform spheroid formation. After 24 h, medium containing collagen
I was added, and the cells were allowed to aggregate further. After
sufficient growth of the spheroids (Day 4 &#8211; <xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>), the cells were treated
with 100 &#956;M of <bold>1</bold> for 48 h. The higher concentration
was chosen, as it has been reported that spheroids require higher
drug doses than two-dimensional (2D) experiments.</p><fig position="float" id="fig10" fig-type="figure" orientation="portrait"><label>10</label><caption><p>(A) Brightfield monitoring
of 3D spheroid growth size over 4 days
and (B) Brightfield and fluorescent images of 3D spheroids using a
live/dead viability assay kit after 48 h of treatment with 100 &#956;M
of compound <bold>1</bold> (bottom row) or untreated cells (top row).
The green fluorescent Calcein A stains proliferating cells, and red
ethidium homodimer-I stains dead cells. Microscope images were collected
using a Zeiss Observer 7 inverted microscope. Scale bar = 500 &#956;m.</p></caption><graphic id="gr11" position="float" orientation="portrait" xlink:href="ic5c02026_0010.jpg"/></fig><p>Live and dead cells were then visualized using
the LIVE/DEAD Viability/Cytotoxicity
Kit by Invitrogen. The green fluorescent Calcein A stains proliferating
cells, and red ethidium homodimer-I stains dead cells. Based on the
images in <xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>, the treated sample shows more dead cells, evidenced by increased
red fluorescence, particularly at the spheroid&#8217;s periphery,
compared to the control. This suggests that the compound is effective
at targeting peripheral cells, likely due to greater drug availability
in the outer layer. Given that the tumor core often lacks oxygen and
is naturally more prone to cell death, the ability to target and affect
the peripheral cells becomes especially crucial for effective treatment.</p></sec></sec><sec id="sec3"><title>Conclusions</title><p>Four charged Cp*-Ir&#173;(III) complexes of the
type [Cp*Ir&#173;(<bold>L1&#8211;4</bold>)&#173;(PTA)]&#173;(PF<sub>6</sub>) (where <bold>L1&#8211;4</bold> = a functionalized
&#946;-ketoiminate ligand and PTA = 1,3,5-triaza-7-phosphaadamantane
ligand) have been successfully synthesized and characterized. NMR
studies demonstrate excellent stability of the compounds in DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>/D<sub>2</sub>O mixtures, even in the presence
of NaCl, as no changes are observed over 96 h. However, when exposed
to fully supplemented media at 37 &#176;C, decomposition is evident
and dependent on the substitution pattern, with compounds <bold>1</bold> and <bold>3</bold> being the most stable, which fully decompose
after 90 and &gt;96 h, respectively. Their cytotoxicity values have
been
determined against a range of cancerous and noncancerous cell lines
and highlight high cytotoxicity and selectivity toward breast cancers.</p><p>This study provides insights into the DNA interaction and apoptotic
effects of the most active compound <bold>1</bold>, comparing its
efficacy with that of cisplatin (CDDP). Cell death assessments indicated
that <bold>1</bold> effectively induces apoptosis, as evidenced by
increased staining with AO/EtBr, Annexin V positivity, caspase activation,
and PARP cleavage. Morphological analysis further confirmed typical
apoptotic features such as DNA condensation and fragmentation, with <bold>1</bold> demonstrating greater apoptotic induction than CDDP in both
MDA-MB-231 and MCF-7 cells. These findings suggest that <bold>1</bold> is capable of triggering apoptosis through mechanisms involving
caspase activation and DNA damage response inactivation, with similar
mechanisms of action as other reported Cp*-Ir&#173;(III) complexes.<named-content content-type="bibref-group">
<xref rid="ref32" ref-type="bibr"/>,<xref rid="ref33" ref-type="bibr"/>
</named-content>
</p><p>The 3D spheroid models offered a more realistic evaluation
of the
potential for <bold>1</bold> to act as an effect anticancer agent,
showing significant cytotoxicity, particularly targeting the peripheral
cells of the spheroid. This observation highlights the compound&#8217;s
ability to impact regions where drug availability is higher, making
it a promising candidate for further development.</p><p>Overall, the
findings suggest that compound <bold>1</bold> has
potential as an anticancer agent, selectively inducing apoptosis in
cancer cells while showing distinct response kinetics compared to
cisplatin. Further studies are needed to better understand its mechanism
of action, optimize its efficacy, and confirm its potential for clinical
applications.</p></sec><sec id="sec4"><title>Experimental Section</title><p>The general synthetic method and
characterization data of compounds <bold>1&#8211;4</bold> are stated
here, and all other general methods,
protocols, spectroscopic analysis, and biological assays are given
in the <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link>.</p><sec id="sec4.1"><title>General Synthetic Method of Compounds <bold>1&#8211;4</bold>
</title><p>&#946;-ketominate ligands <bold>L1&#8211;4</bold> were
all prepared according to our previous literature methods.<named-content content-type="bibref-group">
<xref rid="ref17" ref-type="bibr"/>&#8722;<xref rid="ref18" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref19" ref-type="bibr"/>
</named-content> Compounds <bold>1&#8211;4</bold> were prepared by stirring the
functionalized ligand <bold>L1&#8211;4</bold> (2 equiv) and triethylamine
(2 equiv) in dichloromethane (10 mL). The mixture was stirred at RT
for 10 min before adding [Cp*IrCl<sub>2</sub>]<sub>2</sub> (1 equiv),
and stirring was continued overnight. The solvent was removed <italic toggle="yes">in vacuo</italic>, resuspended in ethanol (10 mL), and 1,3,5-triaza-7-phosphaadamantane
(PTA, 2 equiv) added. The mixture was stirred at RT for 1 h, before
adding ammonium hexafluorophosphate (2 equiv) and stirring was continued
for 30 min. An orange precipitate formed, which was filtered and washed
with cold ethanol and diethyl ether and left to dry under reduced
pressure.</p></sec><sec id="sec4.2"><title>Characterization of Compounds <bold>1&#8211;4</bold>
</title><sec id="sec4.2.1"><title>[Cp*Ir&#173;(C<sub>16</sub>H<sub>14</sub>NO)&#173;(PTA)]&#173;(PF<sub>6</sub>)
(<bold>1</bold>)</title><p>
<bold>L1</bold> (24.9 mg, 0.105 mmol); Et<sub>3</sub>N (15 &#956;L, 0.108 mmol); [Cp*IrCl<sub>2</sub>]<sub>2</sub> (40.4 mg, 0.0507 mmol); PTA (16.7 mg, 0.106 mmol); NH<sub>4</sub>PF<sub>6</sub> (17.0 mg, 0.104 mmol) were used. <italic toggle="yes">
<bold>Yield:</bold>
</italic> 58 mg, 0.067 mmol, 64%; <sup>1</sup>H NMR ((CD<sub>3</sub>)<sub>2</sub>CO, 500 MHz, 298 K, &#948;): 8.06&#8211;8.03 (m, 2H,
Ar&#8211;CH), 7.56 (m, 3H, Ar&#8211;CH), 7.49 (app tt, 2H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 7.8
Hz, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 1.4 Hz Ar&#8211;CH), 7.28 (tt, 1H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 7.5 Hz, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 1.2 Hz, Ar&#8211;CH),
7.21 (br. d, 2H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 7.6 Hz, Ar&#8211;CH), 6.01 (s, 1H, methine CH), 4.65&#8211;4.53
(m, 6H, NCH<sub>2</sub>N PTA), 4.48 (s, 6H, PCH<sub>2</sub>N PTA),
1.92 (s, 3H, CH<sub>3</sub>), 1.49 (d, 15H, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>31</sup>P) = 2.3 Hz, Cp*-CH<sub>3</sub>); <sup>31</sup>P&#173;{<sup>1</sup>H} NMR ((CD<sub>3</sub>)<sub>2</sub>CO, 202 MHz, 298 K, &#948;): &#8722;61.35 (s, 1P, PTA), &#8722;144.25
(sept, 1P, <sup>1</sup>
<italic toggle="yes">J</italic>(<sup>31</sup>P&#8211;<sup>19</sup>F) = 705 Hz, PF<sub>6</sub>); <sup>13</sup>C&#173;{<sup>1</sup>H} NMR ((CD<sub>3</sub>)<sub>2</sub>CO, 100 MHz, 298 K, &#948;):
170.2 (Q, C&#8211;O), 166.7 (Q, C&#8211;N), 153.2 (Q, Ar&#8211;C),
138.6 (Q, Ar&#8211;C), 131.4 (Ar&#8211;CH), 129.7 (Ar&#8211;CH),
127.6 (Ar&#8211;CH), 127.5 (Ar&#8211;CH), 100.8 (methine CH), 95.7
(Q, d, <sup>2</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) = 2.2 Hz, Cp*-C), 73.5 (d, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) = 5.8 Hz, NCH<sub>2</sub>N PTA),
50.4 (d, <sup>1</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) = 13.5 Hz, PCH<sub>2</sub>N PTA), 25.6 (CH<sub>3</sub>), 9.1 (Cp*-CH<sub>3</sub>); HR-MS calculated for the complex cation
C<sub>32</sub>H<sub>41</sub>IrN<sub>4</sub>OP<sup>+</sup> (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>, 100%): 721.2643; Found: 721.2647;
Elemental analysis calculated for C<sub>32</sub>H<sub>41</sub>F<sub>6</sub>IrN<sub>4</sub>OP<sub>2</sub>: C 44.39, H 4.77, N 6.47%, Found:
C 44.05, H 4.74, N 6.38%.</p></sec><sec id="sec4.2.2"><title>[Cp*Ir&#173;(C<sub>16</sub>H<sub>12</sub>Cl<sub>2</sub>NO)&#173;(PTA)]&#173;(PF<sub>6</sub>) (<bold>2</bold>)</title><p>
<bold>L2</bold> (22.8 mg, 0.0745
mmol); Et<sub>3</sub>N (10 &#956;L, 0.717 mmol); [Cp*IrCl<sub>2</sub>]<sub>2</sub> (29.2 mg, 0.0366 mmol); PTA (11.3 mg, 0.0719 mmol);
NH<sub>4</sub>PF<sub>6</sub> (12.1 mg, 0.0745 mmol) were used. Yield:
44 mg, 0.047 mmol, 63%; <sup>1</sup>H NMR ((CD<sub>3</sub>)<sub>2</sub>CO, 500 MHz, 298 K, &#948;): 7.65 (d, 1H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 8.3 Hz, Ar&#8211;CH), 7.61
(d, 1H, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 2.1 Hz, Ar&#8211;CH), 7.61&#8211;7.53 (br. s, 2H, Ar&#8211;CH),
7.50 (dd, 1H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 8.3 Hz, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 2.1 Hz, Ar&#8211;CH), 7.28 (br. tt, 1H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 7.4 Hz, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 1.2
Hz, Ar&#8211;CH), 7.22 (br. d, 2H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 7.8 Hz, Ar&#8211;CH), 5.42
(s, 1H, methine CH), 4.71&#8211;4.63 (m, 6H, NCH<sub>2</sub>N PTA),
4.53 (s, 6H, PCH<sub>2</sub>N PTA), 1.87 (s, 3H, CH<sub>3</sub>),
1.46 (d, 15H, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>31</sup>P) = 2.4 Hz, Cp*-CH<sub>3</sub>); <sup>31</sup>P&#173;{<sup>1</sup>H} NMR ((CD<sub>3</sub>)<sub>2</sub>CO, 202 MHz, 298 K, &#948;):
&#8722;61.05 (s, 1P, PTA), &#8722;144.26 (sept, 1P, <sup>1</sup>
<italic toggle="yes">J</italic>(<sup>31</sup>P&#8211;<sup>19</sup>F) = 705 Hz,
PF<sub>6</sub>); <sup>13</sup>C&#173;{<sup>1</sup>H} NMR ((CD<sub>3</sub>)<sub>2</sub>CO, 100 MHz, 298 K, &#948;): 170.5 (Q, C&#8211;O),
166.9 (Q, C&#8211;N), 153.0 (Q, ArC-N), 138.7 (Q, ArC-O), 135.9 (Q,
ArC-Cl), 132.2 (Q, ArC-Cl), 131.7 (Ar&#8211;CH), 130.7 (Ar&#8211;CH),
128.8 (Ar&#8211;CH), 127.9 (Ar&#8211;CH), 105.7 (methine CH), 95.8
(Q, d, <sup>2</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) = 2.1 Hz, Cp*-C), 73.5 (d, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) = 5.8 Hz, NCH<sub>2</sub>N PTA),
50.20 (d, <sup>1</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) = 13.6 Hz, PCH<sub>2</sub>N PTA), 25.5 (CH<sub>3</sub>), 9.2 (Cp*-CH<sub>3</sub>); HR-MS calculated for the complex cation
C<sub>32</sub>H<sub>39</sub>Cl<sub>2</sub>IrN<sub>4</sub>OP<sup>+</sup> (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>, 100%): 789.1849; Found:
789.1856; Elemental analysis calculated C<sub>32</sub>H<sub>39</sub>Cl<sub>2</sub>F<sub>6</sub>IrN<sub>4</sub>OP<sub>2</sub>: C 41.12,
H 4.21, N, 5.99%, Found: C 41.21, H 3.87, N 5.82%.</p></sec><sec id="sec4.2.3"><title>[Cp*Ir&#173;(C<sub>16</sub>H<sub>13</sub>BrNO)&#173;(PTA)]&#173;(PF<sub>6</sub>) (<bold>3</bold>)</title><p>
<bold>L3</bold> (19.8 mg, 0.0625 mmol);
Et<sub>3</sub>N (10 &#956;L, 0.0717); [Cp*IrCl<sub>2</sub>]<sub>2</sub> (24.9 mg, 0.0313 mmol); PTA (9.80 mg, 0.0624 mmol); NH<sub>4</sub>PF<sub>6</sub> (10.2 mg, 0.0626 mmol) were used. Yield: 27 mg, 0.029
mmol, 46%; <sup>1</sup>H NMR ((CD<sub>3</sub>)<sub>2</sub>CO, 500
MHz, 298 K, &#948;): 8.00 (app. dt, 2H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 8.7 Hz, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 2.6 Hz Ar&#8211;CH),
7.66 (app. dt, 2H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 8.7 Hz, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 2.6 Hz, Ar&#8211;CH), 7.56 (br. s, 2H, Ar&#8211;CH),
7.28 (tt, 1H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 7.5 Hz, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 1.1 Hz, Ar&#8211;CH), 7.20 (br. d, 2H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 7.8 Hz, Ar&#8211;CH),
6.02 (s, 1H, methine CH), 4.65&#8211;4.54 (m, 6H, NCH<sub>2</sub>N PTA), 4.46 (s, 6H, PCH<sub>2</sub>N PTA), 1.91 (s, 3H, CH<sub>3</sub>), 1.48 (d, 15H, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>31</sup>P&#8211;<sup>1</sup>H) = 2.3 Hz, Cp*-CH<sub>3</sub>); <sup>31</sup>P&#173;{<sup>1</sup>H} NMR ((CD<sub>3</sub>)<sub>2</sub>CO, 202 MHz, 298 K, &#948;):
&#8722;61.35 (s, 1P, PTA), &#8722;144.25 (sept, 1P, <sup>1</sup>
<italic toggle="yes">J</italic>(<sup>31</sup>P&#8211;<sup>19</sup>F) = 705 Hz,
PF6); <sup>13</sup>C&#173;{<sup>1</sup>H} NMR ((CD<sub>3</sub>)<sub>2</sub>CO, 100 MHz, 298 K, &#948;): 168.6 (Q, C&#8211;O), 166.9 (Q, C&#8211;N),
153.2 (Q, ArC-N), 137.8 (Q, ArC-O), 132.8 (Ar&#8211;CH), 129.5 (Ar&#8211;CH),
127.7 (Ar&#8211;CH), 125.3 (Q, ArC-Br), 100.7 (methine CH), 95.7
(Q, d, <sup>2</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) = 2.2 Hz, Cp*-C), 73.5 (d, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) = 5.9 Hz, NCH<sub>2</sub>N PTA),
50.3 (d, <sup>1</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) = 13.5 Hz, PCH<sub>2</sub>N PTA), 25.6 (CH<sub>3</sub>), 9.1 (Cp*-CH<sub>3</sub>); HR-MS calculated for the complex cation
C<sub>32</sub>H<sub>40</sub>BrIrN<sub>4</sub>OP<sup>+</sup> (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>, 100%): 799.1732; Found: 799.1739;
Elemental analysis calculated C<sub>32</sub>H<sub>40</sub>BrF<sub>6</sub>IrN<sub>4</sub>OP<sub>2</sub>: C 40.68, H 4.27, N 5.93%, Found:
C 40.66, H 3.86, N 5.74%.</p></sec><sec id="sec4.2.4"><title>[Cp*Ir&#173;(C<sub>18</sub>H<sub>18</sub>NO<sub>2</sub>)&#173;(PTA)]&#173;(PF<sub>6</sub>) (<bold>4</bold>)</title><p>
<bold>L4</bold> (23.7 mg, 0.0842
mmol); Et<sub>3</sub>N (11 &#956;L, 0.0789 mmol); [Cp*IrCl<sub>2</sub>]<sub>2</sub> (32.2 mg, 0.0404 mmol); PTA (13.2 mg, 0.0840 mmol);
NH<sub>4</sub>PF<sub>6</sub> (13.6 mg, 0.0834 mmol) were used. Yield:
53 mg, 0.058 mmol, 69%; <sup>1</sup>H NMR ((CD<sub>3</sub>)<sub>2</sub>CO, 500 MHz, 298 K, &#948;): 8.01 (app. dt, 2H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 9.0 Hz, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 3.0 Hz,
Ar&#8211;CH), 7.59&#8211;7.50 (br s, 2H, Ar&#8211;CH), 7.26 (tt,
1H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 7.4 Hz, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 1.0, Ar&#8211;CH), 7.19 (br. dd, 2H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 7.2 Hz, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 1.3 Hz,
Ar&#8211;CH), 7.00 (app. dt, 2H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 8.9 Hz, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 3.1 Hz, Ar&#8211;CH), 5.94
(s, 1H, methine CH), 4.65&#8211;6.51 (m, 6H, NCH<sub>2</sub>N PTA),
4.45 (s, 6H, PCH<sub>2</sub>N PTA), 4.14 (q, 2H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 7.0 Hz, Ar-OCH<sub>2</sub>CH<sub>3</sub>), 1.90 (s, 3H, CH<sub>3</sub>), 1.48 (d, 15H, <sup>4</sup>
<italic toggle="yes">J</italic>(<sup>31</sup>P&#8211;<sup>1</sup>H) =
2.3 Hz, Cp*-CH<sub>3</sub>), 1.40 (t, 3H, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>1</sup>H&#8211;<sup>1</sup>H) = 7.0 Hz, Ar-OCH<sub>2</sub>CH<sub>3</sub>); <sup>31</sup>P&#173;{<sup>1</sup>H} NMR ((CD<sub>3</sub>)<sub>2</sub>CO, 202 MHz, 298 K, &#948;): &#8722;61.43 (s, 1P,
PTA), &#8211; 144.25 (sept, 1P, <sup>1</sup>
<italic toggle="yes">J</italic>(<sup>31</sup>P&#8211;<sup>19</sup>F) = 705 Hz, PF6); <sup>13</sup>C&#173;{<sup>1</sup>H} NMR ((CD<sub>3</sub>)<sub>2</sub>CO, 100 MHz, 298 K, &#948;):
170.2 (Q, C&#8211;O), 166.2 (Q, C&#8211;O), 162.2 (Q, ArC-N), 153.3
(Q, ArC-O), 130.6 (Q, ArC-O), 129.4 (Ar&#8211;CH), 127.4 (Ar&#8211;CH),
126.3 (Q, Ar&#8211;C), 115.4 (Ar&#8211;CH), 99.7 (methine CH), 95.6
(Q, d, <sup>2</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) = 2.2 Hz, Cp*-C), 73.45 (d, <sup>3</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) = 6.1 Hz, NCH<sub>2</sub>N PTA),
64.5&#173;(Ar-OCH<sub>2</sub>CH<sub>3</sub>), 50.4 (d, <sup>1</sup>
<italic toggle="yes">J</italic>(<sup>13</sup>C&#8211;<sup>31</sup>P) = 13.6 Hz, PCH<sub>2</sub>N PTA), 25.5 (CH<sub>3</sub>), 15.2 (Ar-OCH<sub>2</sub>CH<sub>3</sub>), 9.1 (Cp*-CH<sub>3</sub>); HR-MS calculated for the complex
cation C<sub>34</sub>H<sub>45</sub>IrN<sub>4</sub>O<sub>2</sub>P<sup>+</sup> (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic>, 100%): 765.2906;
Found: 765.2912; Elemental analysis calculated for C<sub>34</sub>H<sub>45</sub>F<sub>6</sub>IrN<sub>4</sub>O<sub>2</sub>P<sub>2</sub>&#183;H<sub>2</sub>O: C 44.01, H 5.11, N 6.04%, Found: C 43.79, H 4.65, N 5.81%.</p></sec></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="ic5c02026_si_001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ACK-d14e1977-autogenerated"><p>The authors would like to thank Orfhlaith McCullough at the
London Metropolitan University for elemental analysis and the UKRI
Future Leader Fellow scheme [MR/T041315/1] for funding of B.J.H.,
Y.H.L. and R.M.L. The authors also express their sincere appreciation
for the services and facilities provided by the Ko&#231; University
Research Center for Translational Medicine (KUTTAM).</p></ack><notes id="notes-1" notes-type="si"><p>The Supporting Information
is available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.inorgchem.5c02026?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.inorgchem.5c02026</ext-link>.<list list-type="simple" id="silist"><list-item><p>General methods; NMR spectroscopy; scxXRD data; NMR
stability studies in 90/10 DMSO-<italic toggle="yes">d</italic>
<sub>6</sub>/D<sub>2</sub>O; stability of compounds <bold>1-4</bold> in supplemented
media over 96 h; high resolution mass spectrometry for compounds <bold>1&#8211;4</bold> (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.inorgchem.5c02026/suppl_file/ic5c02026_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item></list>
</p></notes><notes id="notes-2" notes-type="author-contributions"><label>&#8711;</label><p>T.S. and
B.Y. contributed equally to this work. The manuscript
was written through the contributions of all authors. All authors
have approved the final version of the manuscript.</p></notes><notes id="NOTES-d14e1979-autogenerated" notes-type="conflict-of-interest"><p>The authors declare no
competing financial interest.</p></notes><glossary><def-list specific-use="delimiter-char:, " id="dl1"><title>Abbreviations</title><def-item><term>AO</term><def><p>acridine
orange</p></def></def-item><def-item><term>ARPE-19</term><def><p>noncancerous
retinal epithelial
cells</p></def></def-item><def-item><term>CARB</term><def><p>carboplatin</p></def></def-item><def-item><term>CDDP</term><def><p>cisplatin</p></def></def-item><def-item><term>Cp*</term><def><p>1,2,3,4,5-pentamethylcyclopentadienyl</p></def></def-item><def-item><term>DCF</term><def><p>dichlorofluorescein</p></def></def-item><def-item><term>DNA</term><def><p>DNA</p></def></def-item><def-item><term>EtBr</term><def><p>ethidium bromide</p></def></def-item><def-item><term>H<sub>2</sub>DCFDA</term><def><p>2&#8242;,7&#8242;-dichlorodihydrofluorescein
diacetate</p></def></def-item><def-item><term>IC<sub>50</sub>
</term><def><p>half maximal inhibitory concentration</p></def></def-item><def-item><term>MCF-7</term><def><p>epithelial breast adenocarcinoma</p></def></def-item><def-item><term>MDA-MB-231</term><def><p>epithelial
breast adenocarcinoma</p></def></def-item><def-item><term>MIA PaCa-2</term><def><p>epithelial pancreas carcinoma</p></def></def-item><def-item><term>NMR</term><def><p>nuclear magnetic resonance</p></def></def-item><def-item><term>PARP</term><def><p>poyl&#173;(ADP-ribose) polymerase</p></def></def-item><def-item><term>PF<sub>6</sub>
</term><def><p>hexafluorophosphate</p></def></def-item><def-item><term>PGM</term><def><p>platinum group
metals</p></def></def-item><def-item><term>PTA</term><def><p>1,3,5-triaza-7-phosphaadamantane</p></def></def-item><def-item><term>ROS</term><def><p>reactive oxygen
species</p></def></def-item><def-item><term>scXRD</term><def><p>single
crystal X-ray diffraction</p></def></def-item><def-item><term>SD</term><def><p>standard deviation</p></def></def-item><def-item><term>SEM</term><def><p>standard error of measurement</p></def></def-item><def-item><term>SI</term><def><p>selectivity index</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Rabik</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Dolan</surname><given-names>M. E.</given-names></name><article-title>Molecular Mechanisms of Resistance and Toxicity Associated
with Platinating Agents</article-title><source>Cancer Treat. Rev.</source><year>2007</year><volume>33</volume><issue>1</issue><fpage>9</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2006.09.006</pub-id><pub-id pub-id-type="pmid">17084534</pub-id><pub-id pub-id-type="pmcid">PMC1855222</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Kelland</surname><given-names>L.</given-names></name><article-title>The Resurgence
of Platinum-Based Cancer Chemotherapy</article-title><source>Nat.
Rev. Cancer</source><year>2007</year><volume>7</volume><issue>8</issue><fpage>573</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1038/nrc2167</pub-id><pub-id pub-id-type="pmid">17625587</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Adhikari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nath</surname><given-names>P.</given-names></name><name name-style="western"><surname>Das</surname><given-names>A.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baildya</surname><given-names>N.</given-names></name><name name-style="western"><surname>Duttaroy</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>S.</given-names></name><article-title>A Review on Metal Complexes and Its
Anti-Cancer Activities: Recent Updates from in Vivo Studies</article-title><source>Biomed. Pharmacother.</source><year>2024</year><volume>171</volume><elocation-id>116211</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2024.116211</pub-id><pub-id pub-id-type="pmid">38290253</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Leung</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>D. S. H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D. L.</given-names></name><article-title>Bioactive
Iridium
and Rhodium Complexes as Therapeutic Agents</article-title><source>Coord. Chem. Rev.</source><year>2013</year><volume>257</volume><issue>11&#8211;12</issue><fpage>1764</fpage><lpage>1776</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2013.01.034</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Almodares</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Crossley</surname><given-names>B. D.</given-names></name><name name-style="western"><surname>Basri</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Pask</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Hebden</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>P. C.</given-names></name><article-title>Rhodium, Iridium,
and Ruthenium Half-Sandwich Picolinamide Complexes as Anticancer Agents</article-title><source>Inorg. Chem.</source><year>2014</year><volume>53</volume><issue>2</issue><fpage>727</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1021/ic401529u</pub-id><pub-id pub-id-type="pmid">24397747</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Corral</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hotze</surname><given-names>A. C. G.</given-names></name><name name-style="western"><surname>Dulk</surname><given-names>H. D.</given-names></name><name name-style="western"><surname>Leczkowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rodger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hannon</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Reedijk</surname><given-names>J.</given-names></name><article-title>Ruthenium Polypyridyl
Complexes and Their Modes of Interaction with DNA: Is There a Correlation
between These Interactions and the Antitumor Activity of the Compounds?</article-title><source>JBIC, J. Biol. Inorg. Chem.</source><year>2009</year><volume>14</volume><issue>3</issue><fpage>439</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1007/s00775-008-0460-x</pub-id><pub-id pub-id-type="pmid">19085018</pub-id><pub-id pub-id-type="pmcid">PMC3036821</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Hartinger</surname><given-names>C. G.</given-names></name><article-title>A Multifaceted
Approach towards Organometallic Anticancer Agent Development</article-title><source>J. Organomet. Chem.</source><year>2024</year><volume>1012</volume><elocation-id>123144</elocation-id><pub-id pub-id-type="doi">10.1016/j.jorganchem.2024.123144</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Romero-Canel&#243;n</surname><given-names>I.</given-names></name><name name-style="western"><surname>Habtemariam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Clarkson</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Sadler</surname><given-names>P. J.</given-names></name><article-title>Potent Half-Sandwich
Iridium&#173;(III)
Anticancer Complexes Containing C<sup>&#8743;</sup>N-Chelated and
Pyridine Ligands</article-title><source>Organometallics</source><year>2014</year><volume>33</volume><issue>19</issue><fpage>5324</fpage><lpage>5333</lpage><pub-id pub-id-type="doi">10.1021/om500644f</pub-id><pub-id pub-id-type="pmid">25328266</pub-id><pub-id pub-id-type="pmcid">PMC4195516</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Gasser</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>I.</given-names></name><name name-style="western"><surname>Metzler-Nolte</surname><given-names>N.</given-names></name><article-title>Organometallic
Anticancer Compounds</article-title><source>J. Med. Chem.</source><year>2011</year><volume>54</volume><issue>1</issue><fpage>3</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1021/jm100020w</pub-id><pub-id pub-id-type="pmid">21077686</pub-id><pub-id pub-id-type="pmcid">PMC3018145</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Peacock</surname><given-names>A. F. A.</given-names></name><name name-style="western"><surname>Sadler</surname><given-names>P. J.</given-names></name><article-title>Medicinal Organometallic
Chemistry: Designing Metal
Arene Complexes as Anticancer Agents</article-title><source>Chem.
- Asian J.</source><year>2008</year><volume>3</volume><issue>11</issue><fpage>1890</fpage><lpage>1899</lpage><pub-id pub-id-type="doi">10.1002/asia.200800149</pub-id><pub-id pub-id-type="pmid">18712745</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Murray</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Babak</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Hartinger</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Dyson</surname><given-names>P. J.</given-names></name><article-title>The Development
of RAPTA Compounds for the Treatment of Tumors</article-title><source>Coord. Chem. Rev.</source><year>2016</year><volume>306</volume><issue>P1</issue><fpage>86</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2015.06.014</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>M&#225;likov&#225;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Masaryk</surname><given-names>L.</given-names></name><name name-style="western"><surname>&#352;tarha</surname><given-names>P.</given-names></name><article-title>Anticancer
Half-Sandwich Rhodium&#173;(III)
Complexes</article-title><source>Inorganics</source><year>2021</year><volume>9</volume><issue>4</issue><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.3390/inorganics9040026</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Parveen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hanif</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>K. K. H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Astin</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Zoysa</surname><given-names>G. H.</given-names></name><name name-style="western"><surname>Steel</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Movassaghi</surname><given-names>S.</given-names></name><name name-style="western"><surname>S&#246;hnel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sarojini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jamieson</surname><given-names>S. M. F.</given-names></name><name name-style="western"><surname>Hartinger</surname><given-names>C. G.</given-names></name><article-title>Anticancer
Organorhodium and -Iridium Complexes with
Low Toxicity in Vivo but High Potency in Vitro: DNA Damage, Reactive
Oxygen Species Formation, and Haemolytic Activity</article-title><source>Chem. Commun.</source><year>2019</year><volume>55</volume><issue>80</issue><fpage>12016</fpage><lpage>12019</lpage><pub-id pub-id-type="doi">10.1039/C9CC03822A</pub-id><pub-id pub-id-type="pmid">31498360</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Ma</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>C. H.</given-names></name><article-title>Iridium&#173;(III) Complexes Targeting
Apoptotic Cell Death in Cancer Cells</article-title><source>Molecules</source><year>2019</year><volume>24</volume><issue>15</issue><elocation-id>2739</elocation-id><pub-id pub-id-type="doi">10.3390/molecules24152739</pub-id><pub-id pub-id-type="pmid">31357712</pub-id><pub-id pub-id-type="pmcid">PMC6696146</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>De
Palo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Draca</surname><given-names>D.</given-names></name><name name-style="western"><surname>Murrali</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Zacchini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pampaloni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mijatovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maksimovic-Ivanic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>F.</given-names></name><article-title>A Comparative
Analysis of the In Vitro Anticancer Activity of Iridium&#173;(III) {&#951;<sup>5</sup>-C<sub>5</sub>Me<sub>4</sub>R} Complexes with Variable R Groups</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><issue>14</issue><elocation-id>7422</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22147422</pub-id><pub-id pub-id-type="pmid">34299041</pub-id><pub-id pub-id-type="pmcid">PMC8306930</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Petrini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pettinari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pettinari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Therrien</surname><given-names>B.</given-names></name><name name-style="western"><surname>Galindo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scopelliti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dyson</surname><given-names>P. J.</given-names></name><article-title>Cytotoxic Half-Sandwich
Rh&#173;(III) and
Ir&#173;(III) &#946;-Diketonates</article-title><source>Inorg. Chem.</source><year>2017</year><volume>56</volume><issue>21</issue><fpage>13600</fpage><lpage>13612</lpage><pub-id pub-id-type="doi">10.1021/acs.inorgchem.7b02356</pub-id><pub-id pub-id-type="pmid">29053264</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Lord</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Hebden</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Pask</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>I. R.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>P. C.</given-names></name><article-title>Hypoxia-Sensitive
Metal &#946;-Ketoiminato Complexes Showing Induced Single-Strand
DNA Breaks and Cancer Cell Death by Apoptosis</article-title><source>J. Med. Chem.</source><year>2015</year><volume>58</volume><issue>12</issue><fpage>4940</fpage><lpage>4953</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00455</pub-id><pub-id pub-id-type="pmid">25906293</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Lucas</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Sridharan</surname><given-names>V.</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>P. C.</given-names></name><article-title>Synthesis of Iridium
and Ruthenium Complexes with (N,N),
(N,O) and (O,O) Coordinating Bidentate Ligands as Potential Anti-Cancer
Agents</article-title><source>Dalton Trans.</source><year>2012</year><volume>41</volume><issue>45</issue><fpage>13800</fpage><lpage>13802</lpage><pub-id pub-id-type="doi">10.1039/c2dt32104a</pub-id><pub-id pub-id-type="pmid">23015068</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Lord</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Zegke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>I. R.</given-names></name><name name-style="western"><surname>Pask</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Shepherd</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>P. C.</given-names></name><article-title>&#946;-Ketoiminato
Iridium&#173;(III) Organometallic Complexes:
Selective Cytotoxicity towards Colorectal Cancer Cells HCT116 P53-/-</article-title><source>Chem. - Eur. J.</source><year>2019</year><volume>25</volume><issue>2</issue><fpage>495</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1002/chem.201804901</pub-id><pub-id pub-id-type="pmid">30362193</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Ang</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Daldini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Scolaro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Scopelliti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Juillerat-Jeannerat</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dyson</surname><given-names>P. J.</given-names></name><article-title>Development of Organometallic
Ruthenium-Arene
Anticancer Drugs That Resist Hydrolysis</article-title><source>Inorg.
Chem.</source><year>2006</year><volume>45</volume><issue>22</issue><fpage>9006</fpage><lpage>9013</lpage><pub-id pub-id-type="doi">10.1021/IC061008Y</pub-id><pub-id pub-id-type="pmid">17054361</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Pettinari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marchetti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Condello</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pettinari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lupidi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Scopelliti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mukhopadhyay</surname><given-names>S.</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dyson</surname><given-names>P. J.</given-names></name><article-title>Ruthenium&#173;(II)-Arene
RAPTA Type Complexes
Containing Curcumin and Bisdemethoxycurcumin Display Potent and Selective
Anticancer Activity</article-title><source>Organometallics</source><year>2014</year><volume>33</volume><issue>14</issue><fpage>3709</fpage><lpage>3715</lpage><pub-id pub-id-type="doi">10.1021/om500317b</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Lucas</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Basri</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Blacker</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>P. C.</given-names></name><article-title>Increasing
Anti-Cancer Activity with
Longer Tether Lengths of Group 9 Cp* Complexes</article-title><source>Dalton Trans.</source><year>2016</year><volume>45</volume><issue>16</issue><fpage>6812</fpage><lpage>6815</lpage><pub-id pub-id-type="doi">10.1039/C6DT00186F</pub-id><pub-id pub-id-type="pmid">26924272</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Romero-Canel&#245;n</surname><given-names>I.</given-names></name><name name-style="western"><surname>Qamar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hearn</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Habtemariam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>N. P. E.</given-names></name><name name-style="western"><surname>Pizarro</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Clarkson</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Sadler</surname><given-names>P. J.</given-names></name><article-title>The Potent
Oxidant Anticancer Activity of Organoiridium
Catalysts</article-title><source>Angew. Chem., Int. Ed.</source><year>2014</year><volume>53</volume><issue>15</issue><fpage>3941</fpage><lpage>3946</lpage><pub-id pub-id-type="doi">10.1002/anie.201311161</pub-id><pub-id pub-id-type="pmcid">PMC4227564</pub-id><pub-id pub-id-type="pmid">24616129</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><article-title>Phenoxide Chelated Ir&#173;(III) N-Heterocyclic Carbene Complexes:
Synthesis, Characterization, and Evaluation of Their in Vitro Anticancer
Activity</article-title><source>Dalton Trans.</source><year>2018</year><volume>47</volume><issue>39</issue><fpage>13781</fpage><lpage>13787</lpage><pub-id pub-id-type="doi">10.1039/C8DT03159B</pub-id><pub-id pub-id-type="pmid">30238113</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Du</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><article-title>Fluorescent Half-Sandwich Phosphine-Sulfonate
Iridium&#173;(III) and Ruthenium&#173;(II)
Complexes as Potential Lysosome-Targeted Anticancer Agents</article-title><source>Dyes Pigm.</source><year>2019</year><volume>162</volume><fpage>821</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1016/j.dyepig.2018.11.009</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>&#344;ezn&#237;&#269;kov&#225;</surname><given-names>E.</given-names></name><name name-style="western"><surname>B&#225;rta</surname><given-names>O.</given-names></name><name name-style="western"><surname>Milde</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kry&#353;tof</surname><given-names>V.</given-names></name><name name-style="western"><surname>&#352;tarha</surname><given-names>P.</given-names></name><article-title>Anticancer
Dinuclear Ir&#173;(III) Complex Activates Nrf2
and Interferes with NAD&#173;(H) in Cancer Cells</article-title><source>J. Inorg. Biochem</source><year>2025</year><volume>262</volume><elocation-id>112704</elocation-id><pub-id pub-id-type="doi">10.1016/j.jinorgbio.2024.112704</pub-id><pub-id pub-id-type="pmid">39255589</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Hearn</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Romero-Canel&#243;n</surname><given-names>I.</given-names></name><name name-style="western"><surname>Munro</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Rubio-Ruiz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Carragher</surname><given-names>N. O.</given-names></name><name name-style="western"><surname>Sadler</surname><given-names>P. J.</given-names></name><article-title>Pharmaco-Genomic Investigations of Organo-Iridium Anticancer
Complexes Reveal Novel Mechanism of Action</article-title><source>Metallomics</source><year>2018</year><volume>10</volume><issue>1</issue><fpage>93</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1039/C7MT00242D</pub-id><pub-id pub-id-type="pmid">29131211</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Zhang</surname><given-names>W. Y.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Bridgewater</surname><given-names>H. E.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J. I.</given-names></name><name name-style="western"><surname>Breeze</surname><given-names>B. G.</given-names></name><name name-style="western"><surname>Clarkson</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Coverdale</surname><given-names>J. P. C.</given-names></name><name name-style="western"><surname>Sanchez-Cano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ponte</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sicilia</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sadler</surname><given-names>P. J.</given-names></name><article-title>Ligand-Centred
Redox Activation of Inert Organoiridium Anticancer Catalysts</article-title><source>Chem. Sci.</source><year>2020</year><volume>11</volume><issue>21</issue><fpage>5466</fpage><lpage>5480</lpage><pub-id pub-id-type="doi">10.1039/D0SC00897D</pub-id><pub-id pub-id-type="pmid">34094073</pub-id><pub-id pub-id-type="pmcid">PMC8159363</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Gomes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lima</surname><given-names>J. L. F. C.</given-names></name><article-title>Fluorescence Probes Used for Detection
of Reactive Oxygen Species</article-title><source>J. Biochem. Biophys.
Methods</source><year>2005</year><volume>65</volume><issue>2&#8211;3</issue><fpage>45</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.jbbm.2005.10.003</pub-id><pub-id pub-id-type="pmid">16297980</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Sergi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bulut</surname><given-names>I.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Waller</surname><given-names>Z. A. E.</given-names></name><name name-style="western"><surname>Yildizhan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Acilan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>R. M.</given-names></name><article-title>Understanding the
Potential In Vitro
Modes of Action of Bis&#173;(&#946;-Diketonato) Oxovanadium&#173;(IV) Complexes</article-title><source>ChemMedChem</source><year>2021</year><volume>16</volume><issue>15</issue><fpage>2402</fpage><lpage>2410</lpage><pub-id pub-id-type="doi">10.1002/cmdc.202100152</pub-id><pub-id pub-id-type="pmid">33856120</pub-id><pub-id pub-id-type="pmcid">PMC8453837</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Edmondson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Broglie</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Adcock</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><article-title>Three-Dimensional Cell
Culture Systems and Their Applications in Drug Discovery and Cell-Based
Biosensors</article-title><source>ASSAY Drug Dev. Technol.</source><year>2014</year><volume>12</volume><issue>4</issue><fpage>207</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1089/adt.2014.573</pub-id><pub-id pub-id-type="pmid">24831787</pub-id><pub-id pub-id-type="pmcid">PMC4026212</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Habtemariam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pizarro</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Kisova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vrana</surname><given-names>O.</given-names></name><name name-style="western"><surname>Salassa</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bruijnincx</surname><given-names>P. C. A.</given-names></name><name name-style="western"><surname>Clarkson</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Brabec</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sadler</surname><given-names>P. J.</given-names></name><article-title>Organometallic Half-Sandwich
Iridium Anticancer Complexes</article-title><source>J. Med. Chem.</source><year>2011</year><volume>54</volume><issue>8</issue><fpage>3011</fpage><lpage>3026</lpage><pub-id pub-id-type="doi">10.1021/jm2000932</pub-id><pub-id pub-id-type="pmid">21443199</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Dadci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Elias</surname><given-names>H.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>U.</given-names></name><name name-style="western"><surname>H&#246;rnig</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koelle</surname><given-names>U.</given-names></name><name name-style="western"><surname>Merbach</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Paulus</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J. S.</given-names></name><article-title>&#960;-Arene
Aqua Complexes of Cobalt, Rhodium, Iridium, and Ruthenium: Preparation,
Structure, and Kinetics of Water Exchange and Water Substitution</article-title><source>Inorg. Chem.</source><year>1995</year><volume>34</volume><issue>1</issue><fpage>306</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1021/IC00105A048</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>